A recent study assessed whether neoadjuvant chemotherapy is superior to primary debulking surgery with regard to mortality and quality of life for patients with advanced epithelial ovarian cancer. READ MORE
A recent study assessed whether neoadjuvant chemotherapy is superior to primary debulking surgery with regard to mortality and quality of life for patients with advanced epithelial ovarian cancer.
A recent study found that treatment with PARP inhibitors significantly increases the risk of hematologic toxicities and warrants frequent clinical monitoring by clinicians.
ICER confirmed in a recent report that evidence is lacking for outcomes comparisons of PARP inhibitors to treat ovarian cancer, and that prices should be lowered to increase affordability and patient access.
A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer.
Research in Review
High-grade serous ovarian cancer can be categorized in five molecular subtypes associated with survival and surgical outcomes.
A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment.
Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival and overall survival than those without the antigen.
The treatment landscape in the coming decade for ovarian cancers will likely feature poly ADP ribose polymerase inhibitors in combination with other treatments.
British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.